Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 75

Results For "US"

7512 News Found

NATCO invests US$ 2 million in Cellogen Therapeutics
News | January 18, 2024

NATCO invests US$ 2 million in Cellogen Therapeutics

Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy


Indoco Remedies receives EIR from USFDA for Goa Plant-I
Drug Approval | January 18, 2024

Indoco Remedies receives EIR from USFDA for Goa Plant-I

The PAI was conducted for two drug product applications (ANDAs) filed from this facility


Tritan used for safer medical infusion therapy
Medical Device | January 17, 2024

Tritan used for safer medical infusion therapy

This turn valve is considered revolutionary because it supports back-to-back drug infusion through the same device


Nucala approved in China for use in severe asthma with an eosinophilic phenotype
News | January 16, 2024

Nucala approved in China for use in severe asthma with an eosinophilic phenotype

Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data


30 crore Ayushman cards created under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana
Healthcare | January 15, 2024

30 crore Ayushman cards created under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana

Beneficiaries can create Ayushman Card from their mobile phone using Ayushman App which has been downloaded 52 lakh times since its launch on 13th September, 2023


Ayush gets big boost in the North East
Policy | January 13, 2024

Ayush gets big boost in the North East

India’s First Integrated Ayush Wellness Centre to come up in Guwahati, foundation stone laid


Briefs: Venus Remedies and Shivalik Rasayan
News | January 13, 2024

Briefs: Venus Remedies and Shivalik Rasayan

Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA


USFDA approves Merck’s Keytruda plus chemoradiotherapy with FIGO 2014 stage III-IVA cervical cancer
Drug Approval | January 13, 2024

USFDA approves Merck’s Keytruda plus chemoradiotherapy with FIGO 2014 stage III-IVA cervical cancer

Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients